CLOSE UPDATE: Stocks Hold Post-Jobs Gains, Locked In Razor-Thin Ranges

By
A A A

The stock market closed higher for a second straight session. Stocks ended barely on the plus side as today's Veterans Day holiday limited data and shuttered bond trading, which combined with last week's rally, fostered a lethargic and range-bound session. The Dow Industrials hugged a razor-thin 54 point range, stalling just 6 points below the record high. The Nasdaq shrugged off pressure from momentum and social-media stocks; it closed with very slim gains thanks to gains in Hewlett-Packard ( HPQ ) and a rebound in Twitter ( TWTR ) from early profit-taking pressure.

Global equities were also slightly higher on bullish Chinese economic data, an upgrade in Portugal's government bond rating and better than expected Italian manufacturing data. But like the U.S., trading was stifled by Armistice Day in France and lack of direction from the U.S.

US MARKETS

Dow Jones Industrial Index was up 21 points, +0.1%, at 15,783

S&P 500 was up 1 point, 0.1%, at 1,771

Nasdaq Composite Index was up 0.5 point, or 0.01%, at 3,919

GLOBAL SENTIMENT

FTSE 100 was up 0.30%

Nikkei 225 was up 1.30%

Hang Seng Index was up 1.43%

Shanghai China Composite Index was up 0.16%

UPSIDE MOVERS

FUEL, Upgraded by BMO Capital to Outperform from Market Perform with its price target raised 30% to $65 a share.

GOGO, Reported that Q3 revenue jumped 48% and the company raised the top end of its full-year guidance.

VPHM, Announced a deal to be acquired by Shire for $50 Per Share

NWGO, The company's non-toxic DCVax personalized immune therapies for solid cancer tumors was featured on Fox News and Fox Business News

DOWNSIDE MOVERS

ADXS Announced on Friday the results from its ADXS-HPV treatment for cervical cancer which showed an improvement in the 18-month survival data from 22% to 28%.

CRUS, Barclay's report saying Cirrus Logic is no longer providing certain parts for Apple's ( AAPL ) iPad Air.

ZLCS, Phase 2 clinical studies of Z160 in chronic pain indications did not meet the primary endpoint in patients with lumbosacral radiculopathy (LSR) and post-herpetic neuralgia



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


This article appears in: Investing , Commodities

Referenced Stocks: AAPL , HPQ

MT Newswires

MT Newswires

More from MT Newswires:

Related Videos

Stocks

Referenced

Most Active by Volume

83,946,369
  • $16.40 ▼ 1.20%
65,919,147
  • $102.99 ▲ 0.51%
63,004,409
  • $42 ▲ 4.53%
42,618,740
  • $7.93 ▼ 2.94%
41,388,613
  • $78.37 ▼ 0.41%
40,438,996
  • $3.81 ▲ 14.76%
39,835,674
  • $12.32 ▲ 2.41%
38,147,728
  • $12.83 ▼ 2.80%
As of 10/22/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com